| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥662.8B | ¥604.4B | +9.7% |
| Operating Income | ¥22.3B | ¥20.6B | +8.0% |
| Ordinary Income | ¥22.6B | ¥20.8B | +8.5% |
| Net Income | ¥15.3B | ¥14.1B | +8.3% |
| ROE | 6.6% | 5.9% | - |
FY2026 Q3 consolidated results for Win Partners showed continued growth momentum with revenue of 662.8 billion yen (YoY +9.7%), operating income of 22.3 billion yen (+8.0%), ordinary income of 22.6 billion yen (+8.5%), and net income attributable to owners of 15.3 billion yen (+8.3%). The medical equipment distribution business delivered solid top-line expansion of 58.4 billion yen, though profit growth lagged revenue growth due to margin compression. Total assets increased to 484.6 billion yen from 466.2 billion yen, while total equity decreased to 230.6 billion yen from 240.7 billion yen, reflecting capital policy adjustments including significant treasury stock activity.
Revenue growth of 9.7% was driven by sustained demand in the company's core medical equipment distribution business. The 58.4 billion yen year-over-year increase reflects underlying market expansion in the healthcare sector. On the profit side, gross profit reached 78.2 billion yen with a gross margin of 11.8%, representing a 22 basis point contraction from the prior year's 12.0%. This margin compression indicates pricing pressure or product mix shifts toward lower-margin items. Operating income grew 8.0% to 22.3 billion yen, yielding an operating margin of 3.4%, essentially flat from the prior year's 3.41%. The modest margin improvement suggests that while absolute selling, general and administrative expenses were controlled, they grew nearly in line with revenue. Non-operating items contributed positively, with ordinary income reaching 22.6 billion yen, up 8.5% year-over-year, indicating a small net benefit from financial income or other non-operating activities. Net income growth of 8.3% to 15.3 billion yen was consistent with operating performance, with no material extraordinary items distorting the bottom line. This represents a "revenue up, profit up" pattern, though the profit growth rate slightly lagged revenue growth, highlighting the margin compression challenge.
[Profitability] ROE of 6.6% improved from the prior year, driven by total asset turnover of 1.368 combined with financial leverage of 2.10x, though net profit margin remained modest at 2.3%. Operating margin of 3.4% was essentially unchanged year-over-year, reflecting the structural challenge of maintaining margins in the medical equipment distribution sector. Gross profit margin of 11.8% declined 22 basis points from 12.0%, indicating pricing or mix pressures. [Cash Quality] Cash and deposits stood at 148.9 billion yen, providing coverage of 0.64x against short-term debt and strong liquidity. Days sales outstanding of approximately 94 days reflects the extended credit terms common in medical equipment distribution, with accounts receivable of 170.1 billion yen representing significant working capital deployment. [Investment Efficiency] Total asset turnover of 1.368 indicates efficient asset utilization, with current assets comprising 85.8% of total assets at 416.0 billion yen, reflecting the working capital-intensive nature of the distribution business. [Financial Health] Equity ratio of 47.6% decreased from 51.6% in the prior year, primarily due to the 10.5 billion yen increase in treasury stock holdings from 10.5 billion yen to 20.9 billion yen. Current ratio of 178.2% and quick ratio of 162.4% demonstrate solid short-term liquidity. Debt-to-equity ratio of approximately 1.10x reflects moderate financial leverage.
Cash and deposits increased to 148.9 billion yen, maintaining strong liquidity to support ongoing operations. The working capital position shows accounts receivable of 170.1 billion yen with days sales outstanding of 94 days, indicating extended collection periods typical of medical equipment distribution but representing an area for efficiency improvement. Accounts payable management provides natural financing with the company leveraging supplier credit effectively. The current ratio of 178.2% demonstrates adequate coverage of short-term obligations by liquid assets. Notably, treasury stock increased by 10.5 billion yen during the period, representing a significant capital allocation decision that reduced total equity from 240.7 billion yen to 230.6 billion yen. The cash position provides 0.64x coverage of operating liabilities, indicating sufficient liquidity buffer for operational needs.
Ordinary income of 22.6 billion yen versus operating income of 22.3 billion yen shows a modest non-operating contribution of approximately 0.3 billion yen, representing 0.05% of revenue. This minimal difference indicates that earnings are predominantly driven by core operating activities with limited reliance on non-operating items. The consistency between operating and ordinary income confirms earnings quality is supported by the underlying business rather than financial engineering or one-time gains. Non-operating income components comprise primarily interest and dividend income along with minor financial items, typical for a distribution business. The absence of material extraordinary losses or gains supports the assessment that reported earnings reflect sustainable business performance. With net profit margin of 2.3% and operating margin of 3.4%, the effective tax rate and below-the-line items align with normal operating parameters.
Progress toward full-year guidance shows revenue at 662.8 billion yen representing 79.4% of the 835.0 billion yen target, operating income at 22.3 billion yen or 74.3% of the 30.0 billion yen forecast, ordinary income at 22.6 billion yen or 74.6% of the 30.3 billion yen target, and net income at 15.3 billion yen or 74.6% of the 20.5 billion yen projection. At Q3, the standard expectation would be 75% completion, indicating that the company is tracking slightly below the midpoint on revenue (79.4% vs 75.0% expected) but more closely aligned on profit metrics (74.3-74.6%). The 2.6% year-over-year revenue growth forecast for the full year implies a moderation in Q4 growth versus the 9.7% Q3 cumulative pace, suggesting conservative assumptions or anticipated seasonal factors. The 6.8% forecast growth in both operating and ordinary income implies margin improvement expectations in Q4 to achieve full-year targets given the current 8.0-8.5% profit growth through Q3.
The company forecasts a full-year dividend of 54.0 yen per share, with the fiscal year-end dividend expected at 52.0 yen following a zero interim dividend. Based on the Q3 cumulative net income of 15.3 billion yen and the projected full-year dividend, the payout ratio calculates to approximately 103.8% when applied to Q3 results, indicating that dividends exceed current earnings. However, using the full-year net income guidance of 20.5 billion yen yields a more sustainable payout ratio of approximately 75.3% (54.0 yen divided by forecasted EPS of 71.7 yen). The elevated Q3-based payout ratio reflects the interim nature of the calculation rather than a structural sustainability issue. Notably, the company increased treasury stock holdings by 10.5 billion yen during the period, representing significant share buyback activity. When combined with projected dividend payments of approximately 15.4 billion yen (54.0 yen times outstanding shares), the total shareholder return demonstrates the company's commitment to capital returns despite moderate profitability levels. The total return ratio combining dividends and buybacks relative to earnings warrants monitoring to ensure sustainable capital allocation.
Margin compression risk remains elevated as gross profit margin declined 22 basis points to 11.8% and operating margin stagnated at 3.4%, reflecting competitive pricing pressure in medical equipment distribution and potential adverse product mix shifts that could further compress profitability if volume growth slows. Working capital efficiency risk is evidenced by days sales outstanding of 94 days, which ties up significant capital in accounts receivable totaling 170.1 billion yen and creates vulnerability to customer credit deterioration or payment delays that could strain cash generation. Capital allocation sustainability risk arises from the payout ratio calculation of 103.8% based on Q3 earnings combined with 10.5 billion yen in treasury stock purchases, which together exceed current earnings generation and could pressure financial flexibility if profitability does not improve to meet full-year targets of 20.5 billion yen net income.
[Industry Position] (Reference - Proprietary Analysis)
Win Partners' profitability metrics position near the trading industry median, with ROE of 6.6% aligning closely with the industry median of 6.4%, indicating competitive but not superior return generation. Net profit margin of 2.3% falls below the industry median of 2.7%, while operating margin of 3.4% slightly exceeds the industry median of 3.2%, suggesting operational efficiency is competitive but net profitability faces headwinds from below-operating-line items or effective tax rates. The company's revenue growth of 9.7% significantly outperforms the industry median of 5.0%, demonstrating stronger market position or share gains within the medical equipment distribution sector. Financial health metrics show an equity ratio of 47.6% that exceeds the industry median of 46.4%, indicating conservative capital structure, while the current ratio of 178.2% falls below the industry median of 188.0%, though remaining healthy. Asset turnover of 1.368 surpasses the industry median of 1.00, reflecting efficient asset deployment characteristic of the working capital-intensive distribution model. Days sales outstanding of 94 days compares favorably to the industry median of 78.91 days, suggesting extended credit terms that could represent either competitive necessity or collection efficiency challenges. Financial leverage of 2.10x aligns with the industry median of 2.13x, confirming balanced capital structure positioning. Overall, Win Partners demonstrates above-median revenue growth and asset efficiency while facing below-median net profitability, positioning the company as a growth-oriented operator with margin improvement opportunities relative to trading industry peers.
(Industry: Trading, N=19 companies, Comparison: FY2025 Q3 median values, Source: Proprietary analysis)
Revenue momentum of 9.7% growth significantly outpaces the trading industry median of 5.0%, indicating successful market share expansion or favorable positioning within the medical equipment distribution segment, though this growth has been accompanied by gross margin compression of 22 basis points to 11.8% that warrants close monitoring for sustainability. The combination of 103.8% payout ratio based on Q3 earnings alongside 10.5 billion yen in treasury stock purchases demonstrates aggressive capital returns that depend critically on achieving the full-year net income target of 20.5 billion yen to maintain sustainable shareholder distributions. Working capital management presents both strength and challenge, with asset turnover of 1.368 exceeding industry median efficiency but days sales outstanding of 94 days indicating room for cash conversion improvement that could enhance free cash flow generation without requiring revenue acceleration.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.